drugset / Trial / NCT00097799

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

NCT00097799

Expanded access Approved for marketing Boehringer Ingelheim

Summary

This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.

Timeline

Start
2004-12
Primary completion
2005-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified 200 mg
Subject Tipranavir Small molecule 500 mg